An observational study in Heart Failure, Acute Heart Failure (AHF) and Chronic Heart Failure, sponsored by Fundacion Clinica Valle del Lili. Completed at 119 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by Fundacion Clinica Valle del Lili · Observational
The purpose of this study is to better characterize and understand the population of patients with ambulatory or acutely decompensated heart failure in the American continent, getting to know their sociodemographic, clinical and paraclinical characteristics
An observational, prospective and multicenter study in which ambulatory patients with a confirmed diagnosis of heart failure and those admitted to the hospitalization service due to an episode of acutely decompensated heart failure will be invited to participate in order to better characterize this population
Participants who meet the eligibility criteria will be evaluated at the moment of recruitment. Follow-ups will be performed at 1, 6 and 12 months after the initial registry for hospitalized patients. For ambulatory patients follow-up will only be performed at 12 months. These initial evaluations and subsequents follow-ups will be carried out using a standardized form for the collection of hospital and outpatient data through an electronic platform
The purpose of this study is to know sociodemographic, clinical (clinical presentation, hemodynamic profiles, in-hospital and outpatient management, re-hospitalization rate, proportion of mortality, cumulative survival and heart failure readmission-free survival) and paraclinical characteristics of this population
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's enrollment of 6,732 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Fundacion Clinica Valle del Lili is the lead sponsor of 25 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Heart failure patients with either ambulatory diagnosis or an acute decompensation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Characteristics of population with diagnosis of heart failure in America
Sociodemographic characteristics of patients with heart failure
Time frame: Baseline
Characteristics of population with diagnosis of heart failure in America
Clinical and paraclinical characteristics of patients with heart failure
Time frame: Baseline, at Month 1, Month 6 and Month 12
Outpatient management of heart failure
Describe the ambulatory/outpatient management of patients with heart failure
Time frame: Baseline and at Month 12
Relation between outpatient treatment of heart failure with proportion of hospitalization and mortality
Relate outpatient pharmacological treatment with the proportion of hospitalization and mortality
Time frame: Baseline and at Month 12
Clinical and hemodynamic presentation of acutely decompensated heart failure
Describe the clinical and hemodynamic presentation of patients with acute decompensated heart failure
Time frame: Baseline
In-hospital management of acutely decompensated heart failure
Describe the in-hospital management of patients with acutely decompensated heart failure
Time frame: Baseline
Proportion of in-hospital mortality related with acute decompensation of heart failure
Determine the proportion of in-hospital mortality related with acute decompensation of heart failure
Time frame: Baseline
Proportion of rehospitalization at 1, 6, 12 months after hospital discharge
Determine the proportion of rehospitalization at 1, 6 and 12 months after hospital discharge
Time frame: Month 1, Month 6 and Month 12
Proportion of mortality at 1, 6, 12 months after hospital discharge
Determine the proportion of mortality at 1, 6 and 12 months after hospital discharge
Time frame: Month 1, Month 6 and Month 12
Relation between hemodynamic profile of decompensation with proportion of mortality at 1, 6, 12 months after hospital discharge
Relate the hemodynamic profile of decompensation with the proportion of in-hospital and ambulatory mortality at 1, 6 and 12 months after hospital discharge.
Time frame: Baseline, Month 1, Month 6 and Month 12
Relation between in-hospital pharmacological treatment with mortality at 1, 6, 12 months after hospital discharge
Relate hospital pharmacological treatment with inpatient and outpatient mortality at 1, 6 and 12 months after hospital discharge.
Time frame: Month 1, Month 6 and Month 12
Relation between in-hospital pharmacological treatment with proportion of readmissions at 1, 6, 12 months after hospital discharge
Relate hospital pharmacological treatment with the proportion of readmissions at 1, 6 and 12 months after hospital discharge.
Time frame: Month 1, Month 6 and Month 12
Relation between outpatient pharmacological treatment with proportion of hospitalization and mortality at 1, 6, 12 months after hospital discharge
Relate outpatient pharmacological treatment with the proportion of hospitalization and mortality at 1, 6 and 12 months after hospital discharge.
Time frame: Month 1, Month 6 and Month 12
Differences among heart failure treatment considering sociodemographic characteristics
Describe the differences among inpatient and outpatient treatment taking into account different demographic characteristics such as: gender, age, comorbidities, among others
Time frame: Baseline
Differences among proportion of rehospitalization and heart failure mortality considering sociodemographic characteristics
Describe the differences in the proportion of rehospitalization, hospital and outpatient mortality, taking into account different demographic characteristics: gender, age, comorbidities, among others
Time frame: Baseline
Differences among proportion of rehospitalization and heart failure mortality considering implementation of optimal medical treatment
Describe the differences in the proportion of rehospitalization, hospital and outpatient mortality, taking into account the implementation of optimal or recommended medical treatment in national and international guidelines
Time frame: Baseline, Month 1, Month 6 and Month 12
Differences among hospitalization and heart failure mortality considering the use of cardiac devices
Describe the differences between hospitalization and outpatient mortality taking into account the use of cardiac devices (cardiac resynchronization and/or implantable cardiac defibrillator) recommended in international guidelines
Time frame: Baseline, Month 1, Month 6 and Month 12
Cumulative heart failure survival and readmission-free survival
Evaluate cumulative survival and heart failure readmission-free survival
Time frame: Baseline, Month 1, Month 6 and Month 12
Showing the first 100 of 119 sites across 21 countries. Choose a country and city above to see the rest.
Plan to share: No — We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients
Ran from Apr 2022 to primary completion in Jan 2025, 33 months.
Of 793 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 33 months is below that.
Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion Clinica Valle del Lili